GLT: A Protein Linked To Neurological Disorders (P10948)

Target Name: Glutamate Transporter

NCBI ID: P10948

Glutamate Transporter

Other Name(s): None

GLT: A Protein Linked To Neurological Disorders

The Glutamate Transporter (GLT) is a protein that is expressed in most tissues of the body and is involved in the transport of glutamate, a key signaling molecule in the brain, to its target. Mutations in the GLT gene have been linked to a number of neurological and psychiatric disorders, including epilepsy, schizophrenia, and addiction. As a result, the GLT gene has become a focus of interest for researchers and drug developers.

The GLT protein is a member of the transmembrane protein family, which means that it spans the cell membrane and extends into the cytoplasm. It consists of a catalytic core and an extracellular region that is involved in the interaction with its ligand, glutamate. The core of the GLT protein contains a transmembrane segment that is responsible for the actual transport of glutamate across the membrane.

The GLT gene is located on chromosome 11q22 and has been implicated in a number of neurological and psychiatric disorders. Studies have shown that individuals with certain genetic mutations, such as those in the GLT gene, are at increased risk of developing epilepsy, schizophrenia, and other psychiatric disorders. In addition, individuals with certain mutations in the GLT gene have also been shown to be at increased risk of addiction, as well as other behavioral disorders.

The GLT protein has also been shown to play a role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In these conditions, the GLT protein is expressed abnormally and is thought to contribute to the neurodegeneration that occurs in these diseases.

Despite the importance of the GLT protein in the development and progression of many neurological and psychiatric disorders, much is still not known about its role in these conditions. As a result, the GLT protein has become a target of interest for drug developers and researchers, who are seeking new and effective treatments for these disorders.

One approach to targeting the GLT protein is through the use of small molecules, such as those that can modulate its activity. These small molecules can be used to either activate or inhibit the GLT protein's catalytic activity, allowing researchers to study its role in the development and progression of neurological and psychiatric disorders.

Another approach to targeting the GLT protein is through the use of antibodies, which are laboratory proteins that recognize and bind to specific targets. By using antibodies to target the GLT protein, researchers can study its function in the development and progression of neurological and psychiatric disorders..

In addition to its potential as a drug target, the GLT protein is also of interest as a biomarker for the diagnosis and monitoring of these disorders. For example, the level of GLT protein in brain tissue can be used as a measure of the severity of epilepsy or other psychiatric disorders.

Overall, the GLT protein is a promising target for the development and treatment of neurological and psychiatric disorders. Further research is needed to fully understand its role in these conditions and to develop effective treatments.

Protein Name: Glutamate Transporter (nonspecified Subtype)

The "Glutamate Transporter Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Glutamate Transporter comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets